Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 212 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drowsiness Clear all
Terminated Phase 4 Interventional Results available

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136
View directory record Official record
Conditions
Insomnia, Fibromyalgia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Plant-based Diet on Postprandial Sleepiness

NCT05706649
View directory record Official record
Conditions
Drowsiness
Interventions
Plant-based diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

NCT03904238
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

NCT03881852
View directory record Official record
Conditions
Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions
AXS-12 (Reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study

NCT02037438
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult, Insomnia, Circadian Rhythm Sleep Disorder, Sleep Related Movement Disorders, Narcolepsy and Hypersomnia, Parasomnia
Interventions
CONV care for the diagnosis and treatment of sleep disorders, PCCM for the diagnosis and treatment of sleep disorders
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 22, 2026, 10:17 PM EDT
Withdrawn Early Phase 1 Interventional

Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia

NCT03626727
View directory record Official record
Conditions
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Interventions
Sodium Oxybate Oral Solution [Xyrem]
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

NCT01196117
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
14 days of placebo therapy, 14 days of CPAP therapy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 3 Interventional

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

NCT07633301
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
TAK-360, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Redwood City, California • Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 10:17 PM EDT
Completed No phase listed Observational

Stress and Vision Fluctuations in Retinitis Pigmentosa

NCT00475254
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 22, 2026, 10:17 PM EDT
Completed No phase listed Observational

Improving the Assessment of Hypersomnolence

NCT02884505
View directory record Official record
Conditions
Disorders of Excessive Somnolence
Interventions
Pupillometry, Psychomotor Vigilance Task, Auditory Evoked Potential, Hypersomnia Severity Index
Device · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT00401284
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
EVT 201
Drug
Lead sponsor
Evotec Neurosciences GmbH
Industry
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT06752668
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750, Placebo
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Auburn, Alabama • Chandler, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

NCT00996320
View directory record Official record
Conditions
Sleep Deprivation, Depression
Interventions
Reduced work hour schedule
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2009 · Synced Oct 22, 2026, 10:17 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Light Exposure to Treat Sleep Disruption in Older People

NCT00427323
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Circadian Rhythm Sleep Disorders, Hypersomnia
Interventions
light exposure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

NCT06961266
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP441, Matching Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Aprepitant to Mitigate Opioids' Cognitive Side Effects

NCT02226601
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 22, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

NCT06358950
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Los Angeles, California • Redwood City, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

NCT02151253
View directory record Official record
Conditions
Nocturia, Daytime Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 22, 2026, 10:17 PM EDT